Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share. The company specializes in the development of therapies for sickle cell anemia. The sales volume of Oxbryta, created by GBT, reached $195 million in 2021. Pfizer intends to accelerate Oxbryta distribution in the regions of the world most affected by sickle cell anemia.
Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share. The company specializes in the development of therapies for sickle cell anemia. The sales volume of Oxbryta, created by GBT, reached $195 million in 2021. Pfizer intends to accelerate Oxbryta distribution in the regions of the world most affected by sickle cell anemia. 
investors.pfizer.com
English (US) 